Editorial & Opinion
Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors.
| العنوان: | Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors. |
|---|---|
| المؤلفون: | Savaliya BP; Department of Surgery, Medical Academy Named after SI Georgievsky of Vernadsky Crimean Federal University, Simferopol 295015, Crimea, Russia. bansisavaliya33@gmail.com., Shekouhi R; Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Florida, Gainesville, FL 32608, United States., Mubarak F; Department of Surgery, Aga Khan University, Karachi 74800, Sindh, Pakistan., Manaise HK; Department of Surgery, Government Medical College and Hospital, Chandigarh 160030, Punjab, India., Jimenez PB; Department of Surgery, University of Puerto Rico School of Medicine, San Juan 00921, Puerto Rico., Kowkabany G; Department of Chemical and Biological Engineering, University of Alabama, Tuscaloosa, AL 35487, United States., Popp RA; Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610, United States., Popp K; Department of Surgery, Florida State University, Tallahassee, FL 32306, United States., Gabriel E; Department of Surgery, Mayo Clinic, Jacksonville, FL 32224, United States. |
| المصدر: | World journal of gastroenterology [World J Gastroenterol] 2024 Jun 28; Vol. 30 (24), pp. 3052-3058. |
| نوع المنشور: | Editorial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing : WJG Press, c1998- |
| مواضيع طبية MeSH: | Virus Activation*/drug effects , Hepatitis B virus*/drug effects , Hepatitis B virus*/immunology , Hepatitis B virus*/isolation & purification , Antiviral Agents*/therapeutic use , Antiviral Agents*/adverse effects , Protein Kinase Inhibitors*/adverse effects , Protein Kinase Inhibitors*/therapeutic use , Neoplasms*/drug therapy, Humans ; Hepatitis B/diagnosis ; Hepatitis B/virology ; Hepatitis B/drug therapy ; Risk Factors ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Hepatitis B Surface Antigens/blood |
| مستخلص: | This editorial commented on an article in the World Journal of Gastroenterology titled "Risks of Reactivation of Hepatitis B Virus in Oncological Patients Using Tyrosine Kinase-Inhibitors: Case Report and Literature Analysis" by Colapietro et al . In this editorial, we focused on providing a more comprehensive exploration of hepatitis B virus reactivation (HBVr) associated with the usage of tyrosine kinase inhibitors (TKIs). It includes insights into the mechanisms underlying HBV reactivation, the temporal relationship between TKIs and HBV reactivation, and preventive measures. The aim is to understand the need for nucleos(t)ide analogs (NAT) and serial blood tests for early recognition of reactivation and acute liver injury, along with management strategies. TKIs are considered to be an intermediate (1%-10%) of HBVr. Current guidelines stipulate that patients receiving therapy with high or moderate risks of reactivation or recent cancer diagnosis must have at least tested hepatitis B surface antigen, anti-hepatitis B core antigen (HBc), and anti-hepatitis B surface antibody. Anti-HBc screening in highly endemic areas means people with negative tests should be vaccinated against HBV. Nucleoside or nucleotide analogs (NAs) like entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) form the basis of HBV reactivation prophylaxis and treatment during immunosuppression. Conversely, lamivudine, telbivudine, and adefovir are generally discouraged due to their reduced antiviral efficacy and higher risk of fostering drug-resistant viral strains. However, these less effective NAs may still be utilized in cases where ETV, TDF, and TAF are not feasible treatment options. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| References: | Front Immunol. 2022 Aug 31;13:982346. (PMID: 36119029) World J Gastroenterol. 2024 Mar 7;30(9):1253-1256. (PMID: 38577192) Hepatol Int. 2021 Oct;15(5):1031-1048. (PMID: 34427860) Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. (PMID: 25447850) PLoS One. 2015 Jun 29;10(6):e0131545. (PMID: 26121480) Hepatology. 2009 May;49(5 Suppl):S174-84. (PMID: 19399794) MMWR Recomm Rep. 2023 Mar 10;72(1):1-25. (PMID: 36893044) J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875) Leuk Lymphoma. 2017 Jul;58(7):1764-1766. (PMID: 27892750) Viruses. 2021 Jul 27;13(8):. (PMID: 34452329) Gastroenterology. 2015 Jan;148(1):221-244.e3. (PMID: 25447852) J Gen Intern Med. 2023 Feb;38(2):490-501. (PMID: 36138278) Viruses. 2019 Aug 24;11(9):. (PMID: 31450544) J Clin Med. 2022 Dec 28;12(1):. (PMID: 36615034) J Clin Oncol. 2020 Nov 1;38(31):3698-3715. (PMID: 32716741) JAMA Netw Open. 2021 Apr 1;4(4):e214132. (PMID: 33822067) Front Med (Lausanne). 2022 Jan 14;8:770124. (PMID: 35096867) World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. (PMID: 37731995) Lancet Gastroenterol Hepatol. 2020 Apr;5(4):406-417. (PMID: 32057301) Leuk Res. 2019 Jun;81:95-97. (PMID: 31075669) Clin Exp Hepatol. 2019 Sep;5(3):195-202. (PMID: 31598555) World J Gastroenterol. 2016 Jul 28;22(28):6484-500. (PMID: 27605883) Pharmacotherapy. 2019 Dec;39(12):1190-1203. (PMID: 31596963) Gastroenterology. 2017 May;152(6):1297-1309. (PMID: 28219691) J Hepatol. 2022 Dec;77(6):1670-1689. (PMID: 35850281) JAMA. 2014 Dec 17;312(23):2521-30. (PMID: 25514302) Eur J Cancer. 2019 Aug;117:107-115. (PMID: 31279301) |
| فهرسة مساهمة: | Keywords: Chronic hepatitis B; Hemato-oncology; Hepatitis B virus; Immunomodulators; Immunosuppressant; Nucleoside analogue; Reactivation; Tyrosine-kinase inhibitor |
| المشرفين على المادة: | 0 (Antiviral Agents) 0 (Protein Kinase Inhibitors) 0 (Antineoplastic Agents) EC 2.7.10.1 (Protein-Tyrosine Kinases) 0 (Hepatitis B Surface Antigens) |
| تواريخ الأحداث: | Date Created: 20240710 Date Completed: 20240710 Latest Revision: 20240711 |
| رمز التحديث: | 20240711 |
| مُعرف محوري في PubMed: | PMC11230056 |
| DOI: | 10.3748/wjg.v30.i24.3052 |
| PMID: | 38983963 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2219-2840 |
|---|---|
| DOI: | 10.3748/wjg.v30.i24.3052 |